Advertisement
Advertisement

VSTM

VSTM logo

Verastem, Inc.

6.74
USD
Sponsored
+0.83
+14.04%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

6.75

0.00
+0.07%

Verastem, Inc. Profile

About

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

Info & Links

CEO

Daniel W. Paterson

Headquarters

117 KENDRICK STREET, SUITE 500
NEEDHAM, MA 02494, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.verastem.com

Auditor

Ernst & Young LLP

Share holders

5

Employees

102

Verastem, Inc. Statistics

Valuation Measures

Market Capitalization2

592.71M

Enterprise Value

530.34M

Enterprise Value/EBITDA(ttm)

-3.34

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

6.77

Price to Book(mrq)

7.24

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

84.91%

Operating Margin(ttm)

-231.59%

Profit Margin(ttm)

-336.64%

Return on Equity(ttm)

-492.59%

Return on Invested Capital(ttm)

-233.67%

Return on Assets(ttm)

-93.39%

Income Statement

Revenue(ttm)

87.53M

Revenue Per Share(ttm)

0.97

Gross Profit(ttm)

75.58M

EBITDA(ttm)3

-158.98M

Net Income Available to Common(ttm)

-202.70M

Diluted EPS(ttm)

-2.66

Share Statistics

Beta (5Y Monthly)

0.26

52-Week Change

19.93%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

90.56M

Dividend Yield

0.00%

Float4

86.17M

% Held by Insiders

1.94%

% Held by Institutions

88.37%

Balance Sheet

Total Cash(mrq)

136.35M

Total Cash Per Share(mrq)

1.51

Total Debt(mrq)

73.99M

Total Debt/Equity(mrq)

148.02%

Current Ratio(mrq)

2.25%

Quick Ratio(mrq)

3.00%

Book Value Per Share(mrq)

0.55

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.96

Free Cash Flow(ytd)

-96.03M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement